- Home
- RNTX vs MGLD Comparison
RNTX vs MGLD Comparison
Compare RNTX & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- MGLD
- Stock Information
- Founded
- RNTX 2001
- MGLD 1996
- Country
- RNTX United States
- MGLD United States
- Employees
- RNTX N/A
- MGLD N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- MGLD Finance/Investors Services
- Sector
- RNTX Health Care
- MGLD Finance
- Exchange
- RNTX Nasdaq
- MGLD Nasdaq
- Market Cap
- RNTX 40.3M
- MGLD 35.8M
- IPO Year
- RNTX N/A
- MGLD N/A
- Fundamental
- Price
- RNTX $1.56
- MGLD $1.00
- Analyst Decision
- RNTX
- MGLD
- Analyst Count
- RNTX 0
- MGLD 0
- Target Price
- RNTX N/A
- MGLD N/A
- AVG Volume (30 Days)
- RNTX 33.6K
- MGLD 12.9K
- Earning Date
- RNTX 08-13-2025
- MGLD 05-08-2025
- Dividend Yield
- RNTX N/A
- MGLD N/A
- EPS Growth
- RNTX N/A
- MGLD N/A
- EPS
- RNTX N/A
- MGLD N/A
- Revenue
- RNTX N/A
- MGLD $31,205,000.00
- Revenue This Year
- RNTX N/A
- MGLD N/A
- Revenue Next Year
- RNTX N/A
- MGLD N/A
- P/E Ratio
- RNTX N/A
- MGLD N/A
- Revenue Growth
- RNTX N/A
- MGLD N/A
- 52 Week Low
- RNTX $1.35
- MGLD $0.70
- 52 Week High
- RNTX $4.40
- MGLD $2.10
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- MGLD 58.23
- Support Level
- RNTX N/A
- MGLD $0.80
- Resistance Level
- RNTX N/A
- MGLD $1.04
- Average True Range (ATR)
- RNTX 0.00
- MGLD 0.07
- MACD
- RNTX 0.00
- MGLD 0.01
- Stochastic Oscillator
- RNTX 0.00
- MGLD 77.67
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.